Abstract：
UNASSIGNED: Hedysari Radix Praeparata Cum Melle (HRPCM) and Astragali Radix Praeparata Cum Melle (ARPCM) are used interchangeably in clinics to treat spleen-qi deficiency (SQD) symptom mainly including gastrointestinal dysfunction and decreased immunity, which has unknown differences in efficacy.
UNASSIGNED: To investigate the differences between HRPCM and ARPCM on intervening gastrointestinal- and immune-function with SQD syndrome.
UNASSIGNED: After the SQD model was established, the Sprague-Dawley (SD) rats were randomly divided into nine groups (n = 10): normal; model; Bu-Zhong-Yi-Qi Pills; 18.9, 12.6 and 6.3 g/kg dose groups of HRPCM and ARPCM. Gastrointestinal function including d-xylose, gastrin, amylase vasoactive intestinal peptide, motilin, pepsin, H+/K+-ATPase, Na+/K+-ATPase, sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2) and immune function including spleen and thymus index, blood routine, interleukin (IL)-2, IL-6, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), immunoglobulin (Ig) M, IgA, IgG and delayed-type hypersensitivity (DTH) were detected. Finally, the efficacy differences were analysed comprehensively by the fuzzy matter-element method.
UNASSIGNED: In regulating immune, the doses differences in efficacy between HRPCM and ARPCM showed in the high-dose (18.9 g/kg), but there were no differences in the middle- and low- dose (12.6 and 6.37 g/kg); the efficacy differences were primarily reflected in levels of IL-6, IFN-γ, TNF-α and IgM in serum, and the mRNA expression of IL-6 and IFN-γ in the spleen. In regulating gastrointestinal, the efficacy differences were primarily reflected in the levels of D-xylose, MTL, and GAS in serum, and the mRNA and protein expression of SGLT1 and GLUT2 in jejunum and ileum.
UNASSIGNED: HRPCM is more effective than ARPCM on regulating gastrointestinal function and immune function with SQD syndrome. Therefore, we propose that HRPCM should be mainly used to treat SQD syndrome in the future.
UNASSIGNED: To investigate the differences between HRPCM and ARPCM on intervening gastrointestinal- and immune-function with SQD syndrome.
UNASSIGNED: After the SQD model was established, the Sprague-Dawley (SD) rats were randomly divided into nine groups (n = 10): normal; model; Bu-Zhong-Yi-Qi Pills; 18.9, 12.6 and 6.3 g/kg dose groups of HRPCM and ARPCM. Gastrointestinal function including d-xylose, gastrin, amylase vasoactive intestinal peptide, motilin, pepsin, H+/K+-ATPase, Na+/K+-ATPase, sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2) and immune function including spleen and thymus index, blood routine, interleukin (IL)-2, IL-6, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), immunoglobulin (Ig) M, IgA, IgG and delayed-type hypersensitivity (DTH) were detected. Finally, the efficacy differences were analysed comprehensively by the fuzzy matter-element method.
UNASSIGNED: In regulating immune, the doses differences in efficacy between HRPCM and ARPCM showed in the high-dose (18.9 g/kg), but there were no differences in the middle- and low- dose (12.6 and 6.37 g/kg); the efficacy differences were primarily reflected in levels of IL-6, IFN-γ, TNF-α and IgM in serum, and the mRNA expression of IL-6 and IFN-γ in the spleen. In regulating gastrointestinal, the efficacy differences were primarily reflected in the levels of D-xylose, MTL, and GAS in serum, and the mRNA and protein expression of SGLT1 and GLUT2 in jejunum and ileum.
UNASSIGNED: HRPCM is more effective than ARPCM on regulating gastrointestinal function and immune function with SQD syndrome. Therefore, we propose that HRPCM should be mainly used to treat SQD syndrome in the future.
摘要：
■红芪（HRPCM）和黄芪（ARPCM）在临床上可互换使用，以治疗脾气虚（SQD）症状，主要包括胃肠功能障碍和免疫力下降，在疗效上有未知的差异。
■探讨HRPCM和ARPCM对SQD综合征患者胃肠道和免疫功能干预的差异。
■SQD模型建立后,将SD大鼠随机分为9组（n=10）：正常；模型；补中益气丸；HRPCM和ARPCM的18.9、12.6和6.3g/kg剂量组。胃肠道功能，包括D-木糖，胃泌素,淀粉酶血管活性肠肽，胃动素,胃蛋白酶,H+/K+-ATP酶,Na+/K+-ATP酶,钠-葡萄糖协同转运蛋白1（SGLT1），葡萄糖转运蛋白2（GLUT2）和免疫功能，包括脾脏和胸腺指数，血常规,白细胞介素（IL）-2，IL-6，干扰素-γ（IFN-γ），肿瘤坏死因子-α（TNF-α），免疫球蛋白(Ig)M,IgA,检测IgG和迟发型超敏反应(DTH)。最后,用模糊物元方法综合分析疗效差异。
■在调节免疫，高剂量（18.9g/kg）显示HRPCM和ARPCM之间的剂量差异，但在中剂量和低剂量（12.6和6.37g/kg）没有差异;疗效差异主要反映在IL-6，IFN-γ，血清中TNF-α和IgM,脾脏中IL-6和IFN-γ的mRNA表达。在调节胃肠方面，疗效差异主要反映在D-木糖的水平，MTL,血清中的气体，空肠和回肠中SGLT1和GLUT2的mRNA和蛋白表达。
■HRPCM在调节SQD综合征的胃肠功能和免疫功能方面比ARPCM更有效。因此,我们建议HRPCM未来应主要用于治疗SQD综合征。
■探讨HRPCM和ARPCM对SQD综合征患者胃肠道和免疫功能干预的差异。
■SQD模型建立后,将SD大鼠随机分为9组（n=10）：正常；模型；补中益气丸；HRPCM和ARPCM的18.9、12.6和6.3g/kg剂量组。胃肠道功能，包括D-木糖，胃泌素,淀粉酶血管活性肠肽，胃动素,胃蛋白酶,H+/K+-ATP酶,Na+/K+-ATP酶,钠-葡萄糖协同转运蛋白1（SGLT1），葡萄糖转运蛋白2（GLUT2）和免疫功能，包括脾脏和胸腺指数，血常规,白细胞介素（IL）-2，IL-6，干扰素-γ（IFN-γ），肿瘤坏死因子-α（TNF-α），免疫球蛋白(Ig)M,IgA,检测IgG和迟发型超敏反应(DTH)。最后,用模糊物元方法综合分析疗效差异。
■在调节免疫，高剂量（18.9g/kg）显示HRPCM和ARPCM之间的剂量差异，但在中剂量和低剂量（12.6和6.37g/kg）没有差异;疗效差异主要反映在IL-6，IFN-γ，血清中TNF-α和IgM,脾脏中IL-6和IFN-γ的mRNA表达。在调节胃肠方面，疗效差异主要反映在D-木糖的水平，MTL,血清中的气体，空肠和回肠中SGLT1和GLUT2的mRNA和蛋白表达。
■HRPCM在调节SQD综合征的胃肠功能和免疫功能方面比ARPCM更有效。因此,我们建议HRPCM未来应主要用于治疗SQD综合征。
